Glaukos (GKOS) is back in focus after fresh commentary on robust adoption of its iDose TR glaucoma therapy, a shift that is sharpening attention on how its broader ophthalmic portfolio might support long-term demand trends.

At a share price of $126.34, Glaukos has moved sharply in recent trading, with a 1 day share price return of 3.59% and a 7 day share price return of 14.05% following enthusiasm around iDose TR. The 30 day share price return is down 5.38%, and a 1 year total shareholder return of 32.10% alongside an 89.81% total shareholder return over three years points to momentum that investors are reassessing against the company’s broader glaucoma and retinal therapy pipeline.

If you are comparing Glaukos with other potential healthcare opportunities, this is a good moment to see what else is gaining attention through the 39 healthcare AI stocks

With the stock trading at $126.34 against a widely followed price target of $154.50 and a large indicated intrinsic discount, investors now face a key question: Is Glaukos still undervalued, or is the market already pricing in future growth?

Most Popular Narrative: 16.4% Undervalued

Against a fair value estimate of $151.08, Glaukos at $126.34 sits at a clear discount, and the leading narrative leans heavily on product ramp and long dated guidance to bridge that gap.

Glaukos'' pipeline diversification into corneal health (Epioxa approval expected in late 2025/early 2026), novel glaucoma devices, and early-stage retinal programs positions the company to benefit from increased diagnostic rates and expanding access to ophthalmic interventions globally, providing avenues for future top-line growth and risk mitigation against single-product dependency.

Curious what has to happen for that fair value to hold up? The narrative focuses on brisk revenue expansion, a sharp margin reset, and a premium earnings multiple. The exact mix of those three inputs is where the story really gets interesting.

Result: Fair Value of $151.08 (UNDERVALUED)

However, that upside story can be challenged if reimbursement for key procedures tightens or if adoption of iDose TR and Epioxa falls short of current expectations.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another Way To Look At Valuation

The analyst fair value of $151.08 points to upside, but Glaukos looks expensive on sales at a P/S of 13.5x versus 2.7x for the US Medical Equipment industry, 5.2x for peers, and a fair ratio of 7.5x. That gap raises a simple question: is growth strong enough to justify paying this much for each dollar of revenue?

For a closer look at how those sales based signals stack up against detailed modelling, check out the See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

The mix of enthusiasm and caution in this story is clear, so move quickly, review the underlying data, and weigh the 3 key rewards and 1 important warning sign.

Looking for more investment ideas?

If Glaukos has caught your attention, do not stop here. There are other stocks that might suit your goals, and you do not want to miss them.

• Target potential mispricing by scanning companies that combine quality fundamentals with appealing valuations through the 46 high quality undervalued stocks.
• Strengthen your income stream by reviewing companies offering higher yields and resilient payouts using the 9 dividend fortresses.
• Prioritise resilience by focusing on companies with dependable financial footing via the solid balance sheet and fundamentals stocks screener (46 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.